Clinical trial
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in…
NCT01247324 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT01247324 |
|---|---|
| Title | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis |
| Official title | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo |
| Enrollment | 821 |
| Start date | Aug 31, 2011 |
| Primary completion | Apr 2, 2015 |
| Completion | Dec 31, 2022 |
| First posted | Nov 24, 2010 |
| Last update posted | Mar 4, 2024 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Czechia, Estonia, Finland, France, Germany and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: